Physician profile
Patrick M Grogan
NPI 1801815147
$33,027.45
in general payments reported to CMS, 2019-2025
71 companies · $4,895 in 2025
The $4,895 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,139 · 2020: $4,592 · 2021: $5,013 · 2022: $3,983 · 2023: $4,442 · 2024: $4,964 · 2025: $4,895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $18.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,282.61 |
| Education | $18.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $4,019.25 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Ucb, INC. | $2,743.36 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Acadia Pharmaceuticals INC | $2,617.61 | 2019-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $1,752.14 | 2019-2025 | Ingrezza, Ongentys |
| Acorda Therapeutics, INC | $1,257.07 | 2019-2024 | Inbrija, Ampyra |
| Amneal Pharmaceuticals LLC | $1,123.81 | 2019-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Neurelis, INC. | $1,123.09 | 2021-2025 | Valtoco |
| Medtronic, INC. | $1,030.94 | 2021-2025 | Percept Pc Brainsense, Sensight |
| Abbott Laboratories | $977.74 | 2019-2025 | Infinity, Proclaim |
| Abbvie INC. | $957.06 | 2021-2025 | |
| Lilly USA, LLC | $874.59 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Lundbeck LLC | $812.81 | 2019-2025 | Vyepti, Rexulti |
| Mdd US Operations, LLC | $805.84 | 2020-2025 | Gocovri, Gocovri, Apokyn |
| Kyowa Kirin, INC. | $750.03 | 2020-2024 | Nourianz |
| Nevro Corp. | $737.50 | 2019-2022 |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Grogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.